SENISCA is a spinout company from the University of Exeter, founded in 2020 to develop new approaches to reverse cellular senescence (ageing) and treat diseases and aesthetic aspects of ageing.
SENISCA says it has discovered a new and druggable means to reverse senescence through modulation of RNA splicing. The company’s founders have demonstrated that restoration of splicing factor levels to those seen in younger cells is able to effectively turn back the ageing clock in old cells, bringing about reversal of senescence.
A major cause of age-related diseases and the aesthetic signs of ageing is the accumulation of senescent cells in aged tissues and organs; removal of such cells has been shown to be capable of bringing about ‘rejuvenation’ of function in people and animals.
SENISCA plans to develop treatments for age-related chronic diseases using oligonucleotide-based therapeutic approaches to reset splicing factor levels. The company also plans to develop anti-ageing cosmeceuticals.
Subscribe for alerts on new companies featured on Startups.Bio
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases. Nanobodies® …
ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung …
Alchemab identifies naturally occurring protective antibodies that counter complex diseases, such as cancer and neurodegenerative diseases, by mining the antibody repertoires of individuals who are …
Israel-based Wild Biotech is mining wild animal microbiomes for the discovery of novel human therapeutics, based on the “largest database ever assembled of the microbiome …
MUVON Therapeutics is spin-off from the University of Zurich developing an autologous cell therapy for the treatment of diseases related to skeletal muscle damage or …
Founded in 2020, Chimerna Therapeutics has developed a platform for generating circular RNA, which overcomes the major limitations of RNA therapeutics, namely stability and abundance. …
